Information Provided By: 
Fly News Breaks for March 10, 2017
RDUS
Mar 10, 2017 | 11:06 EDT
JPMorgan analyst Jessica Fye continues to expect FDA approval for Radius Health's abaloparatide despite today's PDUFA delay. Importantly, management noted that the FDA has not asked for any new information, Fye tells investors in a research note. The analyst expects a U.S. launch later this year and recommends using today's selloff as a buying opportunity. She reiterates an Overweight rating on Radius.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
